Skip to content

WellCareChina

Independent medical information for international patients

Menu

Disease

Prostate cancer前列腺癌

ICD-10: C61 — Malignant neoplasm of prostate

Group: Cancer Specialty: Urology

Key figures

Published values only. Every tile opens the section that carries its source, its year and its caliber.

Disease details

Standard Chinese name
前列腺癌
English name
Malignant neoplasm of prostate

Values written in Chinese are quoted as published by the source.

Also known as

  • Prostate cancer
  • PCa

Treatment cost ranges

Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.

Treatment path Cost range Price basis Data year
Surgery 手术 42500 – 60000 CNY Condition package price 病种打包全包价 2020–2021
Radiotherapy 放疗 31000 – 70000 CNY Per-item price 项目价 2025–2026
Chemotherapy 化疗 15000 – 27000 CNY Average per case (full course) 全病程例均 2015–2017
Targeted therapy 靶向 9000 – 79000 CNY Per-item price 项目价 2025
Immunotherapy 免疫 Not applicable Not applicable 不适用 —

The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 79000 CNY. Each row keeps its own data year and caliber.

5 cost ranges for this condition, each with its source on the row page.

Values written in Chinese are quoted as published by the source.

See all cost ranges →

Five-year survival

5-year survival rate 71.1% 95% CI 70.2–71.9

Population
Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
Period
2019–2021
Publisher
National Cancer Center 国家癌症中心
Value nature
Estimated value (hybrid analysis) 估计值（混合法）
Registry scope
281 population-based cancer registries 281 个肿瘤登记处
Stage data availability
Not published

Values written in Chinese are quoted as published by the source.

See all survival rates →

How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.

Hospitals with a published record for this condition

Selected using official public data sources

These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.

How these hospitals were selected

Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.

Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.

Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.

When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.

The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.

  1. Chinese PLA General Hospital中国人民解放军总医院

    Beijing 北京市

    Fudan specialty reputation ranking 2023

    Published research

    PubMed indexes 2 papers on this condition that name this hospital.

    Also ranked: General Surgery #5, Otorhinolaryngology #3, Gastroenterology #4 in the Fudan list.

  2. West China Hospital, Sichuan University四川大学华西医院

    Chengdu 成都市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: General Surgery #3, Thoracic Surgery #4, Otorhinolaryngology #8 in the Fudan list.

  3. Peking University First Hospital北京大学第一医院

    Beijing 北京市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    2 more published studies

    PubMed indexes 4 papers on this condition that name this hospital.

    Also ranked: Infectious Diseases 传染感染 #9, General Surgery nominated, Gynecology nominated in the Fudan list.

  4. Sun Yat-sen Memorial Hospital, Sun Yat-sen University中山大学孙逸仙纪念医院

    Guangzhou 广州市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Published research

    1 more published study

    PubMed indexes 3 papers on this condition that name this hospital.

    Also ranked: General Surgery nominated, Gynecology nominated, Otorhinolaryngology nominated in the Fudan list.

  5. Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院

    Wuhan 武汉市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: General Surgery #6, Gynecology #2, Respiratory Medicine #8 in the Fudan list.

  6. Renji Hospital, Shanghai Jiao Tong University School of Medicine上海交通大学医学院附属仁济医院

    Shanghai 上海市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: Gynecology #10, Gastroenterology #1, Nuclear Medicine 核医学 #8 in the Fudan list.

  7. Peking Union Medical College Hospital中国医学科学院北京协和医院

    Dongcheng District 东城区

    Fudan specialty reputation ranking 2023

    Also ranked: General Surgery #1, Gynecology #1, Otorhinolaryngology #4 in the Fudan list.

  8. The First Affiliated Hospital, Zhejiang University School of Medicine浙江大学医学院附属第一医院

    Hangzhou 杭州市

    Fudan specialty reputation ranking 2023

    National key clinical specialty

    Also ranked: General Surgery #7, Infectious Diseases 传染感染 #2, Thoracic Surgery nominated in the Fudan list.

Clinical trials (investigational treatments)

In addition to standard care, clinical research studies for Prostate cancer may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.

  1. Study A Phase I, Open-Label, Multicenter, First-in-Human, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profiles and Preliminary Efficacy of DXC008 in Patients With Prostate Cancer and Other Solid Tumors (Such as Ewing Sarcoma)

    Hospital
    Hunan Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06926283

  2. Study A Phase 1 Study of DEC003M, an Antibody Drug Conjugate Targeting PSMA, for Advanced Stage Prostate Cancer

    Hospital
    West China Hospital, Sichuan University
    Status
    Recruiting
    Registry
    NCT07657806

  3. Study A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer

    Hospital
    Chongqing University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06095089

  4. Study Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)

    Lead investigator
    Ren Shancheng
    Status
    Recruiting
    Registry
    NCT06238713

  5. Study 99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET

    Lead investigator
    Xiaoyang Zhang · Principal Investigator
    Hospital
    The First Affiliated Hospital of Chongqing Medical University
    Status
    Recruiting
    Registry
    NCT06419348
47 more registered studies

  1. Study Safety and Efficacy Study of Hypofractionated Radiotherapy for Localized Prostate Cancer: a Single-arm Clinical Trial

    Lead investigator
    Zhang Huo Jun
    Status
    Recruiting
    Registry
    NCT06325774

  2. Study Evaluation of Chemotherapy With Adjuvant Docetaxel After Radiotherapy for Localized High Malignant Prostate Cancer: A Prospective Muti-center Non-Randomized Controlled Trial

    Hospital
    Peking University First Hospital
    Status
    Recruiting
    Registry
    NCT06864533

  3. Study Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

    Lead investigator
    Pengyuan Liu · Research Secretary
    Hospital
    Zhejiang Hospital
    Status
    Recruiting
    Registry
    NCT06249750

  4. Study Development of MR Microstructural Imaging Markers for Prostate Cancer Diagnosis and Investigation of the Associated Molecular Mechanisms

    Hospital
    Beijing Hospital
    Status
    Recruiting
    Registry
    NCT07249281

  5. Study A Phase I Study to Assess the Safety, Tolerability, Radiation Dosimetry and Efficacy of [177Lu] Lu-PSMA-XT in Patients With Metastatic Prostate Cancer

    Lead investigator
    Jinming Zhang · PI
    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07096128

  6. Study Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate Cancer

    Hospital
    Shaanxi Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT07531329

  7. Study A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer

    Hospital
    Shaanxi Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT07474142

  8. Study Plasma Exosomal RNA Signature for Predicting PSMA PET-Defined Bone Metastasis in Prostate Cancer: A Prospective, Multicenter Discovery, Development, and Validation Study

    Hospital
    Shaanxi Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT07553754

  9. Study A Phase 1, Open-Label, Multicenter, Dose-Escalation and Dose-Expansion Study of ETB-DualNK-01, an Allogeneic Dual-target PSMA/PSCA CAR-NK Cell Product, in Adults With Metastatic Castration-Resistant Prostate Cancer

    Hospital
    Peking University Shenzhen Hospital
    Status
    Recruiting
    Registry
    NCT07641049

  10. Study A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)

    Hospital
    Peking University First Hospital
    Status
    Recruiting
    Registry
    NCT06925737

  11. Study Evaluation of Dosimetry, Safety, Biodistribution and Preliminary Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer

    Hospital
    The First Affiliated Hospital of Jinan University
    Status
    Recruiting
    Registry
    NCT07468708

  12. Study A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07365995

  13. Study An Exploratory Study of the Safety and Efficacy of Genomic Biomarker-guided Neoadjuvant Therapy for Locally Advanced and Oligometastatic Prostate Cancer (SEGNO)

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06387056

  14. Study PET Targeting Acid Phosphatase 3 (ACP3) in Prostate Cancer and Compared With 68Ga-PSMA

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07242014

  15. Study A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06696326

  16. Study A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

    Hospital
    Anhui Provincial Hospital
    Status
    Recruiting
    Registry
    NCT04986423

  17. Study A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Engaging Agent Targeting Human Kallikrein 2, With or Without JNJ-87189401, a PSMA-CD28 Costimulatory Agent, Plus Best Supportive Care Versus Best Supportive Care for Late-line Metastatic Castration-resistant Prostate Cancer

    Hospital
    Peking University First Hospital
    Status
    Recruiting
    Registry
    NCT07164443

  18. Study A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT07225946

  19. Study The Addictive Diagnostic Value of Apparent Diffusion Coefficients to PI-RADS 3-5 of Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer

    Lead investigator
    XiaoJun · Professor, Chief Physician
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT06737588

  20. Study An Open, Multicenter Phase Ib/II Study on the Safety, Tolerability and Efficacy of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

    Hospital
    Second Affiliated Hospital of Harbin Medical University
    Status
    Recruiting
    Registry
    NCT06568094

  21. Study Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer

    Hospital
    The First Affiliated Hospital of Fujian Medical University
    Status
    Recruiting
    Registry
    NCT07056790

  22. Study The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07552285

  23. Study Rezvilutamide Monotherapy as Adjuvant Treatment for Patients With High Recurrence Risk After Radical Prostatectomy: A Prospective, Multicenter, Single-Arm Study

    Lead investigator
    Hongqian Guo · Chief Physician, Professor, Director of Urology
    Hospital
    Nanjing Drum Tower Hospital
    Status
    Recruiting
    Registry
    NCT07711314

  24. Study A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of HS-20093 or SHR2554 Tablets in Combination With Novel Hormonal Agents in Participants With Metastatic Prostate Cancer

    Hospital
    Nanjing Drum Tower Hospital
    Status
    Recruiting
    Registry
    NCT07230106

  25. Study Diagnostic Value of MRI-targeted Plus Index-lesion-ipsilaterally Systematic Biopsy for Biopsy-naive Men At Risk of Prostate Cancer: a Prospective, Multicenter, Paired, Non-inferiority Trial

    Lead investigator
    Hongqian Guo · Chief physician
    Hospital
    Nanjing Drum Tower Hospital
    Status
    Recruiting
    Registry
    NCT06584279

  26. Study A Prospective, Multicenter, Open-Label, Randomized, Parallel-Group, Noninferiority Trial of MRI/Ultrasound Cognitive Fusion Targeted Biopsy Combined With Ipsilateral Versus Bilateral Systematic Biopsy for Prostate Cancer Diagnosis

    Hospital
    Nanjing Drum Tower Hospital
    Status
    Recruiting
    Registry
    NCT07795723

  27. Study Neoadjuvant ADT +/- Darolutamide Followed by Radical Prostatectomy for High-risk Prostate Cancer: a Randomized, Open Label Trial

    Status
    Recruiting
    Registry
    NCT06575257

  28. Study Serial PSMA PET for Treatment Response Monitoring in Newly Diagnosed Clinically Significant, Treatment-Naïve Prostate Cancer - A Prospective, Multicenter Study

    Hospital
    Shaanxi Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT07553780

  29. Study Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer

    Hospital
    Shaanxi Provincial People's Hospital
    Status
    Recruiting
    Registry
    NCT07492927

  30. Study Post-marketing Clinical Study of Transrectal High-intensity Focused Ultrasound for Localized Prostate Cancer

    Hospital
    Renji Hospital, Shanghai Jiao Tong University School of Medicine
    Status
    Recruiting
    Registry
    NCT06362577

  31. Study Systemic Therapy Combined With Cytoreductive Prostatectomy for the Treatment of de Novo Poly-metastatic Hormone Sensitive Prostate Cancer: A Prospective, Open-label Randomized Controlled Trial

    Lead investigator
    Liang Dong · Associate Research Fellow
    Hospital
    Renji Hospital, Shanghai Jiao Tong University School of Medicine
    Status
    Recruiting
    Registry
    NCT06306612

  32. Study A Head-to-Head Comparison of Targeted and Perilesional Biopsy Versus Combination of Sextant-Systematic Biopsy and Targeted Biopsy for Prostate Cancer Diagnosis: A Randomized Controlled Trial

    Lead investigator
    LIU Yi · Associate chief physician
    Hospital
    Peking University First Hospital
    Status
    Recruiting
    Registry
    NCT07460843

  33. Study Comparison of MRI Artificial Intelligence-guided Cognitive Fusion-targeted Biopsy Versus Routine Cognitive Fusion-targeted Prostate Biopsy in Prostate Cancer Diagnosis: a Multicenter Randomized Controlled Clinical Trial

    Lead investigator
    LIU Yi · Associate chief physician
    Hospital
    Peking University First Hospital
    Status
    Recruiting
    Registry
    NCT06392737

  34. Study Evaluation of Perilesional Biopsy in Diagnosis of Prostate Cancer: a Multicenter Randomized Controlled Trial

    Lead investigator
    LIU Yi · Associate chief physician
    Hospital
    Peking University First Hospital
    Status
    Recruiting
    Registry
    NCT06482645

  35. Study An Exploratory Clinical Study of Rezvilutamide as Adjuvant Therapy for High-Risk Patients After Radical Prostatectomy

    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Not yet recruiting
    Registry
    NCT07444983

  36. Study A Prospective Exploratory Phase II Study on the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer With Darxicilib in Combination With Abiraterone Acetate (II)

    Hospital
    Qilu Hospital of Shandong University
    Status
    Not yet recruiting
    Registry
    NCT06500247

  37. Study A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer

    Hospital
    Chinese PLA General Hospital
    Status
    Not yet recruiting
    Registry
    NCT07641855

  38. Study An Open-Label, Single-Arm, Exploratory Study to Evaluate the Safety and Preliminary Efficacy of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    Lead investigator
    Ren Shancheng
    Status
    Not yet recruiting
    Registry
    NCT07389187

  39. Study An Open-Label, Exploratory Study to Evaluate the Safety and Preliminary Efficacy of LC-K76 in Combination With Endocrine Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer

    Lead investigator
    Ren Shancheng
    Status
    Not yet recruiting
    Registry
    NCT07389174

  40. Study Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy

    Lead investigator
    Liu Cheng · Principal Investigator
    Hospital
    Shanghai General Hospital
    Status
    Not yet recruiting
    Registry
    NCT06608225

  41. Study A Multicenter, Prospective, Single-Arm Clinical Trial Evaluating MRI/Ultrasound Fusion Targeted Biopsy With Intraoperative Frozen Section and Rapid Immunohistochemistry Followed by Immediate Laparoscopic Radical Prostatectomy in Patients With High-Risk Prostate Cancer Identified by the USTC Model

    Lead investigator
    Tao Tao, MD · Associate professor, Associate chief physician
    Hospital
    Anhui Provincial Hospital
    Status
    Not yet recruiting
    Registry
    NCT07709338

  42. Study A Study to Evaluate the Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study

    Lead investigator
    Yong He · Director, Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University
    Hospital
    Zhongnan Hospital of Wuhan University
    Status
    Not yet recruiting
    Registry
    NCT07830212

  43. Study Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer

    Lead investigator
    Ren Shancheng · Professor, Chief of Urology
    Hospital
    West China Hospital, Sichuan University
    Status
    Not yet recruiting
    Registry
    NCT07238959

  44. Study A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate the Diagnostic Efficacy and Safety of INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment

    Hospital
    Beijing Chao-Yang Hospital, Capital Medical University
    Status
    Not yet recruiting
    Registry
    NCT06922929

  45. Study A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate the Diagnostic Efficacy and Safety of INR101 Injection for PET/CT Imaging in Detecting Preoperative Pelvic Lymph Node Metastasis in Patients With Prostate Cancer

    Hospital
    Beijing Chao-Yang Hospital, Capital Medical University
    Status
    Not yet recruiting
    Registry
    NCT06922903

  46. Study Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer: a Phase 2, Multicenter, Open-label, Randomized Controlled Trial

    Lead investigator
    Yung NA · Clinical Assistant Professor
    Hospital
    Huashan Hospital
    Status
    Not yet recruiting
    Registry
    NCT07310433

  47. Study Radioactive Counts From PSMA PET/CT-Targeted Biopsy Specimens for Real-time Diagnosis of Prostate Cancer: A Prospective Study

    Lead investigator
    LIU Yi · Principal Investigator
    Hospital
    Peking University First Hospital
    Status
    Not yet recruiting
    Registry
    NCT07709403

This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.

Hospitals with a national key specialty record

Show the hospital records 30 hospitals with a key-specialty record

Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.

Hospital City Specialty (as published) Evidence Source
Renji Hospital, Shanghai Jiao Tong University School of Medicine上海交通大学医学院附属仁济医院 Shanghai 上海市 Urology 泌尿外科 Level B https://www.renji.com/gh/article/list/01/01
Shanghai General Hospital上海市第一人民医院 Shanghai 上海市 Urology 泌尿外科临床医学中心 Level B https://www.firsthospital.cn/List/Depart/f0
Huashan Hospital复旦大学附属华山医院 Shanghai 上海市 Urology 泌尿外科 Level B https://www.huashan.org.cn/yygk/hsyyjs.htm
China-Japan Friendship Hospital中日友好医院 Beijing 北京市 Urology 泌尿外科 Level B https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
Beijing Hospital北京医院 Beijing 北京市 Urology 泌尿外科 Level B https://www.bjhmoh.cn/index.php?id=4&r=archives/about&t=1790009033
Peking University People's Hospital北京大学人民医院 Beijing 北京市 Urology 泌尿外科 Level B https://www.pkuph.cn/news_details/26715.html
Peking University First Hospital北京大学第一医院 Beijing 北京市 Urology 泌尿外科 Level B https://www.pkufh.com/Html/News/Articles/64494.html
Peking University Third Hospital北京大学第三医院 Beijing 北京市 Urology 泌尿外科 Level B https://www.puh3.net.cn/yygk/zdxk.htm
West China Hospital, Sichuan University四川大学华西医院 Chengdu 成都市 Urology 泌尿外科 Level A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
The First Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院 Hefei 合肥市 Urology 泌尿外科 Level B https://www.ayfy.com/info/1184/27750.htm
The Second Hospital of Shandong University山东大学第二医院 Jinan 济南市 Urology 泌尿外科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Qilu Hospital of Shandong University山东大学齐鲁医院 Jinan 济南市 Urology 泌尿外科 Level A http://wsjkw.shandong.gov.cn/wmfw/cxfw/202307/P020230717441794577839.xlsx
Sun Yat-sen Memorial Hospital, Sun Yat-sen University中山大学孙逸仙纪念医院 Guangzhou 广州市 Urology 泌尿外科 Level B https://www.gzsys.org.cn/basic/453
Sun Yat-sen University Cancer Center中山大学肿瘤防治中心 Guangzhou 广州市 Urology 泌尿外科 Level B https://www.sysucc.org.cn/node/8565
The First Affiliated Hospital, Sun Yat-sen University中山大学附属第一医院 Guangzhou 广州市 Urology 泌尿外科 Level B https://gcp.fahsysu.org.cn/sites/1h.gcp.sysucloud1.sysu.edu.cn/files/2023-07/20230625%20中山大学附属第一医院宣传折页%20V5.0_0.pdf
The Third Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院 Guangzhou 广州市 Urology 泌尿外科 Level B https://www.zssy.com.cn/basic/468
First Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院 Guangzhou 广州市 Urology 泌尿外科 Level B https://www.gyfyyy.cn/cn/news/xwsd/index_88.html
Guangzhou First People's Hospital广州市第一人民医院 Guangzhou 广州市 Urology 泌尿外科 Level B https://oa.gzhosp.cn/col40/list_5
Nanjing Drum Tower Hospital南京鼓楼医院（南京大学医学院附属鼓楼医院） Nanjing 南京市 Urology 泌尿外科 Level B https://www.njglyy.com/zbmz/zbmz2.aspx
First Affiliated Hospital of Zhengzhou University郑州大学第一附属医院 Zhengzhou 郑州市 Urology 泌尿外科 Level B https://www.zdyfy.cn/tsyl/gjjlczdzk
The First Affiliated Hospital, Zhejiang University School of Medicine浙江大学医学院附属第一医院 Hangzhou 杭州市 Urology 泌尿外科 Level A http://zdygb.zju.edu.cn/2014/0106/c34026a1762975/page.htm
Zhejiang Provincial People's Hospital浙江省人民医院 Hangzhou 杭州市 Urology 泌尿外科 Level B https://hospitalstar.com/#/intro/courtyard?id=1&cid=204&fnav=2
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院 Wuhan 武汉市 Urology 泌尿外科 Level B https://www.tjh.com.cn/contents/934/27291.html
Zhongnan Hospital of Wuhan University武汉大学中南医院 Wuhan 武汉市 Urology 泌尿外科 Level B https://www.znhospital.com/Uploads/Picture/2025/03/06/u67c8f245cacb9.pdf
Renmin Hospital of Wuhan University武汉大学人民医院 Wuhan 武汉市 Urology 泌尿外科 Level B https://www.rmhospital.com/article/id/16939.html
Xiangya Hospital of Central South University中南大学湘雅医院 Changsha 长沙市 Urology 泌尿外科 Level B https://www.xiangya.com.cn/zdzk.html
Hunan Provincial People's Hospital湖南省人民医院 Changsha 长沙市 Urology 泌尿外科 Level B http://www.hnsrmyy.com/index.php?catid=117
First Hospital of China Medical University中国医科大学附属第一医院 Shenyang 沈阳市 Urology 泌尿外科 Level B https://www.cmu1h.com/features/specialty
The First Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院 Chongqing 重庆市 Urology 泌尿外科 Level A https://wsjkw.cq.gov.cn/zwgk_242/fdzdgknr/tzgg/gzgs/202412/t20241225_14021980_wap.html
The First Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院 Xi'an 西安市 Urology 泌尿外科 Level B https://news.xjtu.edu.cn/info/1033/17951.htm

30 hospitals with a matching national key specialty record.

Values written in Chinese are quoted as published by the source.

Questions about this condition

We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.

Ask us about this condition

ICD codes

Show the code table 1 ICD code
Version Code Name in that version
ICD-10-WHO C61 Malignant neoplasm of prostate

Rows are the WHO ICD-10 entries for this condition, quoted as published.

Source & evidence

Source URL
https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
Source scheme
https
Source type
Provincial health commission
Evidence level
A - said by a provincial health commission or university
Retrieved on
2026-09-24